Novo, Catalent $16.5B Merger Wins EU Blessing as US Antitrust Scrutiny Mounts

In the U.S., the chorus of opposition against the proposed merger continues to grow and now includes the CEOs of Roche and Lilly, a broad coalition of unions and consumer groups and at least one senator.

Scroll to Top